| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT07098338 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) |
Trial sites expanded: 64 -> 83 locations |
| 2026-05-23 | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or… |
Trial sites reduced: 99 -> 90 locations |
| 2026-05-16 | NCT05374512 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally… |
date change Completion moved earlier: 2028-11-03 -> 2026-12-31 |
| 2026-05-15 | NCT07129993 Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus… |
Trial sites expanded: 80 -> 98 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07357597 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd)… | Stomatitis | Not Yet Recruiting |
| Phase 3 | |||
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's… | Breast Cancer | Recruiting |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab… | Non-small Cell Lung Cancer | Recruiting |
| NCT07205822 | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0… | Breast Cancer | Recruiting |
| NCT05215340 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment… | Metastatic Non Small Cell Lung Cancer | Recruiting |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib… | Metastatic Non-small Cell Lung Cancer | Recruiting |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for… | Non-Small Cell Lung Cancer | Recruiting |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in… | Breast Cancer | Active, Not Recruiting |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy… | Metastatic Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant… | Breast Cancer | Active, Not Recruiting |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and… | NSCLC | Active, Not Recruiting |
| NCT05104866 | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of… | Breast Cancer | Active, Not Recruiting |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally… | Breast Cancer | Active, Not Recruiting |
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus… | Urothelial Cancer | Recruiting |
| Phase 2 | |||
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients… | Endometrial Cancer | Recruiting |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | Breast Cancer | Recruiting |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Breast Neoplasms | Recruiting |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| NCT06954480 | Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in… | Triple Negative Breast Cancer | Recruiting |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | Recruiting |
| Phase 1/2 | |||
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With… | Non-Small Cell Lung Cancer | Recruiting |
| NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in… | Advanced Solid Malignancies | Recruiting |